Investigating the effect of ((WartOver)) ointment in the treatment of skin warts

Phase 2

Recruiting

Conditions: Cutaneous Warts.
Viral warts

Registration Number: IRCT20200509047352N2

Lead Sponsor: Tehran University of Medical Sciences

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Recruiting

Sex: All

Target Recruitment: 60

Inclusion Criteria

Over 18 years of age
The participant is able to understand the conditions and instructions of the clinical trial
The presence of up to 5 skin warts with an area of up to 1 cm
Presence of the lesion at least 4 weeks in the baseline visit
At least 4 weeks have passed since other treatments such as cryotherapy and...
Willing to sign an informed consent to participate in this study

Exclusion Criteria

Pregnancy and lactation
history of skin malignancy and premalignancy (eg, actinic keratosis)
immunodeficiency (eg, due to chemotherapy, glucocorticoids, systemic steroids, genetic immunodeficiency, transplant status, AIDS, etc.)
lesions in the genital area
eyelid involvement
complicated infection
receipt of any human papillomavirus (HPV) vaccine within 6 months of enrollment
any current skin disease or systemic disease (eg, psoriasis, atopic dermatitis, eczema, sun damage) or condition that, in the opinion of the researcher, participating in the study may expose the participant to unnecessary risk or interfere with the conduct of the study or evaluations, such as sunburn, excessive hair, open wounds.

Study & Design

Study Type: interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
umber of patients with complete removal of target cutaneous wart dusing 12 weeks (or less) after treatment. Timepoint: Before initial of treatment and then every month after starting to use wart-over ointment (with palm extract) or placebo until the skin wart is completely removed, the lesion is photographed. The treatment lasts up to 12 weeks. Method of measurement: Reduction of the wart area or its complete removal will be evaluated by the digital lesion photos which are taken before the start of the treatment and then at each visit (monthly) and for a maximum period of 12 weeks, by Image-j software.

Secondary Outcome Measures